Slide 1: Global growth
Uscom (UCM) – Global Medical Devices For personal use only Global growth June 2016 Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO The Measure of Life
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: Uscom global assets for revenue growth
Uscom For personal use only “Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.” 3 Uscom – Medical devices the experts use
Slide 4: Summary
Summary For personal use only Non-invasive cardiovascular pulmonary device manufacturer World leading technologies Global partners, nearing profitability (±$3m revenue) Rapid growth (+40% for 4 years), before transformational revenue and partnerships Uscom BP+ and SpiroSonic for market and revenue F
Slide 5: Business Background
Business Background For personal use only Premium noninvasive cardiovascular and pulmonary monitoring devices Addressing the growing threat of superbugs, heart failure, hypertension and asthma Validated, clinically accepted, cost and life saving devices with critical applications Aggressive global g
Slide 6: Strategic growth
Strategic growth For personal use only Uscom Pulsecor Thor Uscom Limited Limited Kft Limited $50m $50m $50m 2010 2013 2015 2016 Three world leading technologies merged under one operating entity Debt free acquisitions – scrip, raising and operations Rapidly strengthening balance sheet Acquisitive, s
Slide 7: Uscom Recognition
Uscom Recognition For personal use only Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards “A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy” 7 Uscom – Devices the experts
Slide 8: Products and Market
Products and Market For personal use only Multiple high fidelity noninvasive digital medical devices Fluid, Sepsis Hypertension & COPD & Heart Failure Vascular Health & Asthma US 1.3bn market * US 1.7bn market * US 400m market * CAGR of 7.6% * CAGR of 11.5% * CAGR of 6.5% * CE, FDA, TGA, CFDA CE, FD
Slide 9: Products - USCOM 1A
Products - USCOM 1A For personal use only Heart failure, hypertension, sepsis, fluid Non invasive, accurate, compact, platform technology Accurate cardiac output Works with all other hospital equipment Cardiac stroke volume Intuitive touch screen Systemic vascular Real time data resistance Platform
Slide 10: Products - Uscom BP+
Products - Uscom BP+ For personal use only Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension • FDA, CE Mark, TGA approvals • Home or clinic • Supra-systolic • PPW Analysis Oscollometry • Results in • Reliable and 30 seco
Slide 11: Products - Uscom SpiroSonic
Products - Uscom SpiroSonic For personal use only Asthma, COPD, Occupational Lung Disease and drug compliance monitoring • High fidelity digital ultrasonic spirometry • Multi-path ultrasonic sensing • FDA, CE, and TGA approvals • Reliable and accurate • Auto calibration • Research, home and clinic •
Slide 12: Big Data
Big Data For personal use only Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors • Software analytics • Telemetric signals • Cloud based processing/diagnosis • Personalised clinical advice • Medication and dosage • Serial monitoring • Multiple measures • Home
Slide 13: New - tSpiro
New - tSpiro For personal use only Uscom selling technologies others are researching High fidelity telemetric spirometer The future for asthma and COPD • CE, FDA and TGA. CFDA in train • US revenue (more than 400) • Software analytics • Telemetric signals to cloud via iphone • Cloud based processing
Slide 14: New Series
New Series For personal use only Improved diagnosis, management and monitoring of pulmonary diseases tSpirometers - high fidelity telemetric pulmonary monitoring For launch FY 2017 14 Uscom – Devices the experts use
Slide 15: Regulatory
Regulatory For personal use only Uscom is preparing a new generation of products for regulatory approval across multiple jurisdictions for marketing in 2017 USCOM 1A BP+ Uscom BP+ Thor SpiroSonic CE Preparation Preparation (Europe) ✓ ✓ ✓ FDA Preparation Preparation (USA) ✓ ✓ ✓ CFDA Preparation - Pre
Slide 16: BioTechnology Leader
BioTechnology Leader For personal use only Uscom BP+ Thor Granted 12 21 3 Pending 4 1 1 Patents - Real IP, real value, product pipeline 16 Uscom – Devices the experts use
Slide 17: De-Risked Technology
De-Risked Technology For personal use only Featured in 500+ peer reviewed publications and presentations Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsi
Slide 18: Multi-Products
Multi-Products For personal use only Three world leading product ranges entering profit phase Global Profit Concept Product Pilot Validation Regulatory Revenue Distribution FY17 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ ✓ ±✓ Uscom BP+ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ±✓ SpiroSonic ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Investment to Profit 26 IP transformed int
Slide 19: Revenue Targets
Revenue Targets For personal use only SpiroSonic – FY 2017 Total Revenue 20,000,000 18,000,000 16,000,000 BP+ - FY 2017 14,000,000 12,000,000 SpiroSonic $ 10,000,000 BP+ USCOM 8,000,000 USCOM 6,000,000 4,000,000 2,000,000 0 2015 2016* 2017* 2018* 2019* 2020* 19 $20m revenue by 2020 = 5 year CAGR of
Slide 20: The Future
The Future For personal use only Value Cascade Products Sales Operations Opportunities USCOM 1A New appointments Global operations Share price growth Uscom BP+ Current distribution Increased products Dividend BP+Reporter Thor distribution Increased scale Transaction SpiroSonic Completion of New dist
Slide 21: Global Operations
1. Uscom Aus 2. Uscom UK Global Operations 3. 4. Uscom Budapest Uscom USA For personal use only 5. Uscom Shanghai • • •• 2 • •• • • •• • ••• 3 ••• •••4 •• • • • • • 5 • • • • • Key Markets •• 1/5. AsiaPAC • • • 1 2/3. Europe 4. Nth America Focus FY 2017 Asia – Establish CIIC 21 US – BP+ and SpiroSon
Slide 22: China Growth
China Growth David He joins UCM Board Formerly J&J China, For personal use only McKinsey Shanghai China Health Expenditure as % of GDP China Health Spend (USD) 7.9 GDP=12,000,000,000,000 6.5 Health=5.4%=648,000,000,000 Objective=12%=1,400,000,000,000 5.4 4.8 4.8 4.7 4.7 5.1 5.0 5.1 Growth(+6.6%)=$79
Slide 23: News - Uscom CIIC China
News - Uscom CIIC China For personal use only Five year importation and wholesale agreement with Shanghai CIIC Science and Technology Development Corp targeted to generate USD$48.2m (≈A$65m) in sales. CIIC S&T – State owned company CIIC revenue – $10b USD, Med Device Division $250m USD 23 Uscom – Me
Slide 24: CIIC China
CIIC China For personal use only “We plan to make Uscom one of the leading medical device brands in China over the next five years.” Daniel Sun, Head of BD and Marketing, Shanghai CIIC Science and Technology, Medical Device division Shareholder value, if targets achieved - $1.40 per share. ($13m sal
Slide 25: Increasing recognition
Increasing recognition For personal use only Alan Kohler Peter Switzer CNBC Asia Fox TV With improved operational performance has come increased media and international investor interest 25 Uscom – Medical devices the experts use
Slide 26: Increasing recognition
Increasing recognition For personal use only With improved operational performance has come increased media and international investor interest The Australian, 5-3-16 Sarah-Jane Tasker 26
Slide 27: Current objectives
Current objectives For personal use only • Realise CIIC targets • Maintain USCOM 1A growth • Deliver BP+, BP+Reporter, SpiroSonic and SpiroReporter to worldwide markets (products, regulatory and manufacturing) • Continue partnership discussions • Distributors with high reach and reputation • Develop
Slide 28: Operational risks
Operational risks For personal use only • Global medical markets unpredictable • Product development/regulatory slower and more costly than expected • Distribution slow to achieve revenue goals and integrate new products • Costs for acquisitions, product development and production in advance of reve
Slide 29: UCM - Growth trend
UCM – Growth trend For personal use only A blue sky story with de-risked operations UCM Revenue and Income UCM Distribution Agreements $2,500,000 40 38 $2,039,426 $2,000,000 35 30 27 $1,500,000 $1,377,716 25 $1,010,942 20 $1,000,000 15 12 10 $500,000 5 $0 0 2013 2014 2015 2013 2014 2015 Current reve
Slide 30: UCM - Growth trend
UCM – Growth trend For personal use only Revenue and Income $3,000,000 $2,900,000 $2,500,000 $2,039,426 $2,000,000 $1,500,000 $1,377,716 $1,010,942 $1,000,000 $500,000 $0 2013 2014 2015 2016* 2016 - Revenue + cash receipts continue to rise (40± ±% for 4 years) Share price +77% Transformational CIIC
Slide 31: Profitability?
Profitability? UCM Quarterly Cash Receipts 700,000 For personal use only 600,000 500,000 Revenue rising 40% YOY for last 4 years 400,000 $ Margins 60-80% 300,000 2016 YOY cash receipts rising: 200,000 Q1 up 133%, H1 up 71%, Q3 up 112% Q3 cash outflow $55k (near breakeven) 100,000 2016 costs include
Slide 32: Right Sector - Long Term Growth
Right Sector - Long Term Growth For personal use only ASX 10 yr CAGR % pa 14.0 12.1 12.0 10.0 8.0 6.0 UCM sales growth % 4.0 3.5 2014 – 67% 2.0 0.0 0.1 0.0 2015 – 59% S&P 200 Financial NAB Materials BHP RMD Healthcare -2.0 Index (Mining) Index Index -2.4 -4.0 -4.5 -4.3 -6.0 • 1st Feb 2006 – 1st Feb
Slide 33: Right Time for Growth
Right Time for Growth For personal use only Revenue Growth % pa 60 50 40 Uscom 30 Resmed % CSL 20 Cochlear 10 0 2013 2014 2015 -10 26 Right company, right time…..
Slide 34: UCM outperforms market
UCM outperforms market For personal use only 9 BellDirect 20h June 2016 2016 year to date performance…..
Slide 35: Uscom
Uscom For personal use only Value investment ✓ Experienced management ✓ Strong underlying business ✓ Strong growth phase ✓ Invested in growth ✓ Premium global markets ✓ ✓ Diversified and lifesaving technologies✓ Aggressive global growth strategy ✓ ✓ Two new product ranges for market in the next 12mt
Slide 36: Uscom
Uscom For personal use only “Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.” 36 Uscom – Medical devices the experts use
Slide 37: Thank You
Uscom (UCM) – Global Medical Devices For personal use only Global Growth June 2016 Thank You Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO Uscom – Medical devices the ex
Slide 38: USCOM 1A Competitive Advantage
USCOM 1A Competitive Advantage For personal use only Non- SV beat Method Manufacturer Technology Rel+Rep invasive Simple Cost Portable to beat USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ BioZ Samsung BioImpedance ✗ ✓ ✓ ✗ ✓ ✗ NiCOM Cheetah BioReactance ✗ ✓ ✓ ✗ ✓ ✗ Nexfin Bmeye APP ✗ ✓ ✓ ✓ ✓ ✗ CardioQ Deltex D
Slide 39: Testimonials
Testimonials For personal use only “This machine is saving lives, there are no two ways about it.” Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia “USCOM has changed the way I look at the cardiovascular status of my patients. It’s part of t
Slide 40: BP+ Competitive Advantage
BP+ Competitive Advantage For personal use only Uscom BP+ TensioMed BPLab IEM Centron AtCor Australia Hungary Russia Germany UK Australia USD 3,500 USD 6,000 USD 7,000 USD 7,000 USD 6,300 USD 20,000 1 min 2 min 2 min 2 min 1 min 1 min Stand-alone ABP, needs computer ABP, needs computer ABP, needs co
Slide 41: Why ?
Why ? For personal use only Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute – BP+ = Four stars BP+ is on the international space station 36 McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current e
Slide 42: SpiroSonic Competitive Advantage
SpiroSonic Competitive Advantage For personal use only Uscom Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD SpiroSonic Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD
Slide 43: CPT Codes and Re-Imbursement
CPT Codes and Re-Imbursement For personal use only Product Measure Region Code Price (AUD) Status Uscom BP+ Central BP USA 93050 $25.60 S* USCOM 1A Cardiac Output USA 76999 $107.00 S** Cardiac Output China 310701023 $44.00 ✓ Cardiac Output China 220600010 $13.50 ✓ + $2.50 measure Cardiac Output Aust